The 2009 ISI Impact Factors (IFs) have just been released, and Expert Opinion has had a good year:
Expert Opinion on Investigational Drugs = 4.218
Expert Opinion on Therapeutic Targets = 3.713
Expert Opinion on Biological Therapy = 3.215
Expert Opinion on Drug Metabolism and Toxicology = 3.076
Expert Opinion on Drug Safety = 2.496
Expert Opinion on Emerging Drugs = 2.407
Expert Opinion on Pharmacotherapy = 2.018
Expert Opinion on Therapeutic Patents = 1.280
Expert Opinion on Drug Delivery has now received its first IF, emerging with a strong first showing of 3.345.
The IF indicates a publication’s influence within the global research community. In a given year, the IF of a journal reflects the average number of citations to those papers that were published during the two preceding years. Expert Opinion’s 2009 IFs therefore account for the number of articles published from 2007-2008, which were cited in 2009.
Further information on IF’s can be found on the ISI Web of Knowledge website, under Journal Citation Reports.
Monday 28 June 2010
Friday 25 June 2010
Supplementary material for journal articles
On our online platform, informahealthcare.com, we encourage authors to take advantage of our multimedia supplementary material feature when publishing their articles in any Informa Healthcare journal. As an author, you may wish to publish additional files containing information that is peripheral to the conclusions of the paper, but that further demonstrate the results or significance of your work, alongside the main article content that will be printed in an issue. This supplementary material could be valuable to specialist readers, while not necessary for other readers to understand and appreciate the methods and conclusions in the main article files. This material is hosted online together with your article PDF and HTML and is viewable to all subscribers and pay-per-view customers and can, on request (and with agreement of the Editor), be made free to all users.
This feature provides authors with a number of options to further enhance their work. For example, by using video or animated figure files, it is possible to visually demonstrate a biological or technical process. Audio files may be used to support topics discussed in speech and language pathology articles. You can include large data sets within your papers, containing some background information (e.g., genome sequences, gene expression profiles, extended data), which may allow readers to use the information to fully investigate the implications of your research. Surveys, presentation slides and detailed chemical/metabolic pathways are just three more examples of what can be included.
The informahealthcare.com site can accept supplementary material in almost any format, including .doc, .xls, .ppt, .gif, .jpg, .mov, .mp3, .wma, .wav and .pdf. Any supplementary files that you wish to include should be submitted to the editorial office together with the main article files, and will be reviewed as part of the normal manuscript peer-review process. The Editor will make a decision regarding whether the additional content is suitable for inclusion.
Jonathan Collard
Electronic Production Manager
This feature provides authors with a number of options to further enhance their work. For example, by using video or animated figure files, it is possible to visually demonstrate a biological or technical process. Audio files may be used to support topics discussed in speech and language pathology articles. You can include large data sets within your papers, containing some background information (e.g., genome sequences, gene expression profiles, extended data), which may allow readers to use the information to fully investigate the implications of your research. Surveys, presentation slides and detailed chemical/metabolic pathways are just three more examples of what can be included.
The informahealthcare.com site can accept supplementary material in almost any format, including .doc, .xls, .ppt, .gif, .jpg, .mov, .mp3, .wma, .wav and .pdf. Any supplementary files that you wish to include should be submitted to the editorial office together with the main article files, and will be reviewed as part of the normal manuscript peer-review process. The Editor will make a decision regarding whether the additional content is suitable for inclusion.
Jonathan Collard
Electronic Production Manager
Tuesday 22 June 2010
Rising Impact Factors, Strong Growth, Solidifies Journals as Leading Resources
Informa Healthcare – one of the world’s leading medical and scientific publishers – has released its latest Journal Impact Factor* results, with outstanding performances across the division’s diverse selection of peer-reviewed journals.
Highlights included Critical Reviews in Biochemistry and Molecular Biology, which registered a staggering 10.216 Impact Factor, up 23% from 8.306 last year; The World Journal of Biological Psychiatry, increased more than 55% to 5.564; and Chronobiology International jumped up to 3.987.
Impact Factors are a method of measuring the influence which a journal has on the scientific community. They are calculated by Thomson Reuters and are designed to indicate how many times the published articles of a journal are cited during the course of a year, providing an insight to how much ‘impact’ the journal is making on the scientific community.
“The Impact Factor can help validate the importance of our journals to the medical and scientific communities we serve,” explains Phil Garner, Divisional Managing Director at Informa Healthcare.
“We are extremely proud of the high quality information which we publish for our readers and the wide range of healthcare fields covered by our titles. We are delighted that this year’s Impact Factor increases for each journal clearly reflect the quality and importance of the research and pinpoint how much it is being used throughout the year”
Informa’s Expert Opinion series – which provides in-depth analysis of the pharmaceutical R&D pipeline – has registered noteworthy performances in Expert Opinion on Investigational Drugs which increased its Impact Factor to 4.218, and Expert Opinion on Drug Delivery which impressed with a first-ever Impact Factor of 3.345.
“These results demonstrate the comprehensive, intelligent content that makes our Expert Opinion journals the definitive reference source for leading pharmaceutical scientists,” says Phil.
Four other Informa titles to enter the market with a remarkable impact include: Journal of Immunotoxicology with a first-ever impact factor of 1.218; Computer Aided Surgery with an impact factor of 1.221; Logopedics, Phoniatrics Vocology had a 1.175 Impact Factor in its first year; and Australasian Psychiatry entering the market at 0.657.
“We are justifiably proud of the performance of all of our journals,” adds Phil. “Our established journals have continued to move from strength to strength, with many titles solidifying an upward trend in their respective rankings.”
The World Journal of Biological Psychiatry moved up 22 places in the Psychiatry category, while the Amyotrophic Lateral Sclerosis Impact Factor increased 63% to 2.963, moving 37 places up within its Clinical Neurology sector. The Scandinavian Journal of Primary Health Care also moved up 13 places with a 27.9% Impact Factor increase to 2.205.
Other titles that registered impressive Impact Factor performances were: Cancer Investigation, with an increased impact factor of 2.105; Autoimmunity at 2.813; Critical Reviews in Microbiology with 3.207; Leukemia & Lymphoma at 2.397; and Nanotoxicology which registered a 72.5% increase to 5.774.
“Our overall performance – together with the outstanding individual performances of many of our titles – ensures that Informa continues to serve as a leading force in medical and scientific publishing, providing the market with the lion’s share of must-read titles,” explains Phil.
*© Thomson Reuters, Journal Citation Reports® 2010
Highlights included Critical Reviews in Biochemistry and Molecular Biology, which registered a staggering 10.216 Impact Factor, up 23% from 8.306 last year; The World Journal of Biological Psychiatry, increased more than 55% to 5.564; and Chronobiology International jumped up to 3.987.
Impact Factors are a method of measuring the influence which a journal has on the scientific community. They are calculated by Thomson Reuters and are designed to indicate how many times the published articles of a journal are cited during the course of a year, providing an insight to how much ‘impact’ the journal is making on the scientific community.
“The Impact Factor can help validate the importance of our journals to the medical and scientific communities we serve,” explains Phil Garner, Divisional Managing Director at Informa Healthcare.
“We are extremely proud of the high quality information which we publish for our readers and the wide range of healthcare fields covered by our titles. We are delighted that this year’s Impact Factor increases for each journal clearly reflect the quality and importance of the research and pinpoint how much it is being used throughout the year”
Informa’s Expert Opinion series – which provides in-depth analysis of the pharmaceutical R&D pipeline – has registered noteworthy performances in Expert Opinion on Investigational Drugs which increased its Impact Factor to 4.218, and Expert Opinion on Drug Delivery which impressed with a first-ever Impact Factor of 3.345.
“These results demonstrate the comprehensive, intelligent content that makes our Expert Opinion journals the definitive reference source for leading pharmaceutical scientists,” says Phil.
Four other Informa titles to enter the market with a remarkable impact include: Journal of Immunotoxicology with a first-ever impact factor of 1.218; Computer Aided Surgery with an impact factor of 1.221; Logopedics, Phoniatrics Vocology had a 1.175 Impact Factor in its first year; and Australasian Psychiatry entering the market at 0.657.
“We are justifiably proud of the performance of all of our journals,” adds Phil. “Our established journals have continued to move from strength to strength, with many titles solidifying an upward trend in their respective rankings.”
The World Journal of Biological Psychiatry moved up 22 places in the Psychiatry category, while the Amyotrophic Lateral Sclerosis Impact Factor increased 63% to 2.963, moving 37 places up within its Clinical Neurology sector. The Scandinavian Journal of Primary Health Care also moved up 13 places with a 27.9% Impact Factor increase to 2.205.
Other titles that registered impressive Impact Factor performances were: Cancer Investigation, with an increased impact factor of 2.105; Autoimmunity at 2.813; Critical Reviews in Microbiology with 3.207; Leukemia & Lymphoma at 2.397; and Nanotoxicology which registered a 72.5% increase to 5.774.
“Our overall performance – together with the outstanding individual performances of many of our titles – ensures that Informa continues to serve as a leading force in medical and scientific publishing, providing the market with the lion’s share of must-read titles,” explains Phil.
*© Thomson Reuters, Journal Citation Reports® 2010
Computational Sciences in Drug Metabolism and Toxicology
This month Expert Opinion on Drug Metabolism and Toxicology is proud to introduce its first themed issue, focusing on Computational Sciences in Drug Metabolism and Toxicology.
Computational chemistry and bioinformatics have gained considerable importance in the pharmaceutical field to the extent that they are now integrated and indispensable to any R&D programme. This is particularly relevant in drug metabolism and toxicology studies, where in silico methods hold the potential to reduce the attrition rate throughout the drug development cycle and improve regulatory productivity and quality through faster, cheaper and better informed decision making.
Guest Edited by Dr Luis Valerio Jr., an internationally recognized expert in this topic, this issue is very unique and explores, among regulatory perspectives and reviews by leading experts, the variety of approaches in the field, their usage and development. Most importantly, it also stresses the limits of the tools and the need for their thorough understanding, testing and validation before implementation. In his free editorial, Dr Valerio Jr details the coverage of each article, and points out how these tools are evidence-based and represent an integrated science.
I hope you will find the articles insightful and thought provoking.
Joris Roulleau
Senior Editor
Computational chemistry and bioinformatics have gained considerable importance in the pharmaceutical field to the extent that they are now integrated and indispensable to any R&D programme. This is particularly relevant in drug metabolism and toxicology studies, where in silico methods hold the potential to reduce the attrition rate throughout the drug development cycle and improve regulatory productivity and quality through faster, cheaper and better informed decision making.
Guest Edited by Dr Luis Valerio Jr., an internationally recognized expert in this topic, this issue is very unique and explores, among regulatory perspectives and reviews by leading experts, the variety of approaches in the field, their usage and development. Most importantly, it also stresses the limits of the tools and the need for their thorough understanding, testing and validation before implementation. In his free editorial, Dr Valerio Jr details the coverage of each article, and points out how these tools are evidence-based and represent an integrated science.
I hope you will find the articles insightful and thought provoking.
Joris Roulleau
Senior Editor
Friday 18 June 2010
GPR119 agonists for the treatment of type 2 diabetes
Type 2 diabetes mellitus is the most common form of diabetes, already affecting millions of people worldwide, with cases expected to rise significantly in the future. Given some of the unpleasant and sometimes dangerous side effects of current anti-diabetic therapies, which include hypoglycaemia, gastrointestinal problems, weight gain and edema, there is ongoing research to find more promising targets that can effectively reduce blood glucose. One target that has gained considerable interest is GPR119, a G-protein coupled receptor. Agonists of this receptor have been shown to increase both glucose –dependent insulin release and incretin release (which, in turn, causes insulin release). Jones and colleagues review currently known chemical GPR119 agonists focusing on the chemical structure of the compounds and discuss their effects in animal models of diabetes and early clinical trials. The authors claim GPR119 agonists could be used effectively with DPP-IV inhibitors to control glucose levels if their actions can be repeated in human clinical trials.
Tuesday 8 June 2010
Informa Healthcare redesigns website, adds book content
Informahealthcare.com offers improved navigation with new look and ability to search across journals and books
Informa Healthcare – one of the world’s leading medical and scientific publishers¬ – has unveiled plans to redesign and add recently published book content to the informahealthcare.com web platform. The change is set to go live in July 2010, when the site will deliver more than 170 journals and approximately 600 online books. The combination of books and journals allows users to search across both products to find key data on one platform – saving researchers time and helping site administrators track usage more effectively.
The redesigned site will improve navigation and optimize current functionality. Enhancements include:
• Deeper content in special therapeutic areas including cardiology, dermatology, neurology, pharmaceutical science, respiratory medicine, toxicology, and urology
• Option to save searches to help manage advanced research results
• Improved navigation options to highlight most popular articles and chapters, share journal or book developments and connect related content or authors to improve and expand research
• More links to key resources such as audio or video content, social networking pages, users guides, and the Informa Healthcare blog to diversity product offerings and maximize subscription investments
“Adding more electronic content from our recently published books will offer our customers more research and opinion within specific therapeutic areas,” said Phil Garner, Divisional Managing Director, Informa Healthcare. “With additional links to video content and our ability to search across journals or books, we’ll be able to deliver a richer online experience to our customers.”
The new platform also allows librarians, information officers or department heads to evaluate usage and traffic on the site to ensure their patrons or staff are regularly accessing the data and help quantify subscription investments. As administrators, customers can access COUNTER-compliant usage reports, manage IP ranges, and view general account details. Users can also receive new data published online through free alerts services – including eTOC alerts, early online article alerts or RSS feeds to share any research or developments with peers.
Informahealthcare.com covers all aspects of healthcare—including drug discovery and development, medical technology, bioscience, clinical medicine and toxicology—offering access to specialized research and insight from an international body of experts. The site will now offer more than 3 million pages of research and approximately 16,000 new book chapters. Content will continue to increase as new issues and books are added.
For more information, visit http://informahealthcare.com.
Informa Healthcare – one of the world’s leading medical and scientific publishers¬ – has unveiled plans to redesign and add recently published book content to the informahealthcare.com web platform. The change is set to go live in July 2010, when the site will deliver more than 170 journals and approximately 600 online books. The combination of books and journals allows users to search across both products to find key data on one platform – saving researchers time and helping site administrators track usage more effectively.
The redesigned site will improve navigation and optimize current functionality. Enhancements include:
• Deeper content in special therapeutic areas including cardiology, dermatology, neurology, pharmaceutical science, respiratory medicine, toxicology, and urology
• Option to save searches to help manage advanced research results
• Improved navigation options to highlight most popular articles and chapters, share journal or book developments and connect related content or authors to improve and expand research
• More links to key resources such as audio or video content, social networking pages, users guides, and the Informa Healthcare blog to diversity product offerings and maximize subscription investments
“Adding more electronic content from our recently published books will offer our customers more research and opinion within specific therapeutic areas,” said Phil Garner, Divisional Managing Director, Informa Healthcare. “With additional links to video content and our ability to search across journals or books, we’ll be able to deliver a richer online experience to our customers.”
The new platform also allows librarians, information officers or department heads to evaluate usage and traffic on the site to ensure their patrons or staff are regularly accessing the data and help quantify subscription investments. As administrators, customers can access COUNTER-compliant usage reports, manage IP ranges, and view general account details. Users can also receive new data published online through free alerts services – including eTOC alerts, early online article alerts or RSS feeds to share any research or developments with peers.
Informahealthcare.com covers all aspects of healthcare—including drug discovery and development, medical technology, bioscience, clinical medicine and toxicology—offering access to specialized research and insight from an international body of experts. The site will now offer more than 3 million pages of research and approximately 16,000 new book chapters. Content will continue to increase as new issues and books are added.
For more information, visit http://informahealthcare.com.
Subscribe to:
Posts (Atom)
